Editorials: Times, Journal examine interim FDA leader

Editorials in The New York Times and The Wall Street Journal say the resignation of FDA commissioner Lester Crawford gives the Bush administration the opportunity to put effective leadership in place at the agency, and the papers examine Dr. Andrew von Eschenbach as the interim choice. Both editorials say Eschenbach understands the importance of accelerating the drug approval process, and the Journal says Bush should put "real political weight" behind him, while the Times said he requires "hard scrutiny" by the Senate because of "mixed reviews" during his time at the National Cancer Institute.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC